Inducerege Brand Introduction

Preface：
   Human medicine has witnessed two groundbreaking revolutions: the birth of surgery, which made it possible to repair physical trauma, and the widespread application of antibiotics and pharmaceutical drugs, which ended the lethality of infectious diseases. Today, we stand at the threshold of the third medical revolution. Stem cells—the core technology within the field of regenerative medicine—will utterly redefine the meaning of "incurable."
   Rutai Traditional Chinese Medicine Hospital, as a participant in this medical revolution, has been deeply dedicated to the field of regenerative medicine for over two decades. From the company's establishment to its research into core technologies, every step reflects the scientific team's persistent pursuit of applying regenerative medicine and stem cell technology to restore human health.
I.Introduction to Traditional Stem Cell Technology
   The core appeal of stem cell technology lies in its power to turn the “impossible” into the “possible.” Along this journey, humanity has achieved numerous milestone accomplishments. From the initial isolation and cultivation of stem cells to later advances in directed differentiation and applications in regenerative medicine—each step embodies the wisdom and dedication of countless researchers.
   Despite possessing tremendous potential and vast application prospects, stem cell therapy still encounters numerous technical challenges. Existing treatment methods exhibit significant limitations in clinical practice.Firstly, sourcing stem cells presents a fundamental and core challenge. Research most commonly focuses on exogenous stem cells—those derived from external sources such as embryonic tissues, umbilical cord blood, or adult tissues. However, the process of procuring these cells frequently triggers ethical controversies.Furthermore, treatment safety is equally paramount. Once introduced into the human body, critical questions arise: Can these exogenous stem cells be effectively utilized? Will they successfully integrate into existing tissue structures, properly home to target sites, and differentiate accurately?In clinical trials, patients have commonly experienced immune rejection reactions and serious adverse effects, including tumor development (tumorigenesis).
   Therefore, ensuring that stem cells differentiate accurately into specific cell types and effectively avoiding abnormal cell proliferation that may occur during the differentiation process to guarantee their safety and efficacy is a crucial issue that urgently needs to be addressed. Only by overcoming these challenges can stem cell technology in regenerative medicine truly move from the experimental stage to a truly safe and effective stage of clinical application for therapeutic purposes.
II. Introduction to the Research Directions of Regenerative Medicine and Stem Cell Technology in Rutai Traditional Chinese Medicine Hospital
   The research pathway of Rutai Traditional Chinese Medicine Hospital differs from that of traditional regenerative medicine and stem cell technology. Its uniqueness lies in combining regenerative medicine and stem cell technology with traditional Chinese medicine (TCM). Specifically, it regulates the induced differentiation and proliferation of autologous stem cells through extracts from traditional Chinese medicinal materials. This combination not only aims to enhance the safety and efficacy of stem cell therapy but also strives to reduce the risks of immune rejection and abnormal cell proliferation.
   The research team of Rutai Traditional Chinese Medicine Hospital has conducted in-depth exploration into the active components in Chinese medicinal materials. By leveraging the unique biological effects of these components, the team optimizes the differentiation pathway of stem cells to ensure that the stem cells can differentiate accurately into the required cell types. This innovative research direction not only provides new ideas for the development of stem cell technology in regenerative medicine but also opens up new avenues for the application of traditional Chinese medicine (TCM) in the field of modern medicine.
III. Research and Development Origin and Core Figures
   The establishment and continuous development of the Rutai brand rely on the research direction that integrates traditional Chinese medicine (TCM) with regenerative medicine and stem cell technology. This achievement cannot be achieved without the joint efforts of two outstanding individuals: Academician Duan Xuhuang, founder of the Rutai brand, and Dr. Li Ming, core researcher.
   Academician Duan Xuhuang, founder of the Rutai brand, distinguished expert appointed by the Chinese Academy of Sciences (CAS), and leading figure in China's big health industry, has been deeply engaged in the big health industry for more than 30 years. He has founded a number of well-known brands in the big health industry, such as Kangpu Biology—a company that ranks among the top 2 in the world in terms of technological strength, leads China's colostrum industry, and is the developer of China's colostrum technical standards—and enjoys an extremely high reputation in the industry.
   Academician Duan Xuhuang not only has profound attainments in the big health industry, but also holds great enthusiasm and vision for regenerative medicine and stem cell technology. With his forward-looking thinking, Academician Duan Xuhuang keenly perceived the great potential of combining traditional Chinese medicine (TCM) with modern medicine, and resolutely devoted himself to the establishment and development of the Rutai brand. Under his leadership, Rutai Traditional Chinese Medicine Hospital has gradually grown into a research-oriented medical institution integrating scientific research and clinical practice, making outstanding contributions to promoting the integrated innovation of traditional Chinese medicine and modern medicine.
   Dr. Li Ming, the core R&D lead for regenerative medicine and stem cell technology at Rutai, is an outstanding expert in the field. His distinguished academic credentials include an MD from Hokkaido University School of Medicine (Japan), a PhD in Molecular Biology from the University of Wales (UK), the role of Senior Scientific Director at the Cambridge Laboratory, and a postdoctoral fellowship at the University of Texas Southwestern Medical Center (USA). His professional appointments have also included Professor in the Department of Cardiology at the Chinese University of Hong Kong School of Medicine, Director of the Hong Kong Regenerative Medicine Laboratory, and FDA Drug Application Consultant for HuYa Bioscience International(USA). He leads and supervises six distinct R&D teams, comprising numerous professors and PhDs, including 2006 Nobel Laureate Craig Mello.
   Dr. Li Ming focuses on the induced differentiation and proliferation regulation of stem cells, and has conducted in-depth research on the active components in Chinese medicinal materials. With his solid professional knowledge and innovative spirit, Dr. Li Ming continuously optimizes the differentiation pathway of stem cells to ensure that stem cells can differentiate accurately into the required cell types, making important contributions to the research work of Rutai Traditional Chinese Medicine Hospital.
IV. Current Scientific Research Achievements of Rutai Traditional Chinese Medicine Hospital
   Over the past two decades, our team has conducted in-depth and extensive research and exploration in the field of regenerative medicine. Through unremitting efforts, we have finally achieved a series of major breakthroughs, successfully discovering and developing an innovative therapeutic method that we call "autologous stem cell targeted differentiation inducer". A number of important scientific research achievements have been obtained through clinical and animal trials. This groundbreaking progress has completely subverted traditional medical cognition, and at the same time addressed the irreversible status of many major human diseases, bringing new hope to a large number of patients!
1. Core Scientific Research Achievement
   Discovery and Development of an Innovative Regenerative Medicine Therapeutic Component: Geum japonicum Extract EGJ (Autologous Stem Cell-Targeted Differentiation Inducer)
2. Core Functions
   "Vascular Regeneration" and "Cell Regeneration"，this technology can induce and activate the expression of genes and miRNAs in the specific signaling pathway for angiogenesis. It promotes the establishment of collateral circulation and microcirculation in ischemic areas, and also stimulates stem cells to differentiate directionally into functional vascular endothelial cells and tissue cells, thereby repairing damaged tissues and organs.
Vascular Regeneration
   By inducing and activating the expression of genes and miRNAs in the specific signaling pathway for angiogenesis through drugs, the establishment of collateral circulation and microcirculation in ischemic areas is promoted.
Cell Regeneration
   It promotes the differentiation and homing of stem cells, repairs tissue cells that have become dysfunctional or lost due to ischemia, restores their normal physiological functions, and exhibits significant therapeutic effects on diseases of vital human organs such as cardiovascular diseases, cerebrovascular diseases, and liver diseases.
V. Scientific Research Strength and Intellectual Property Rights
   In the process of combining regenerative medicine and stem cell technology with traditional Chinese medicine (TCM), Rutai Traditional Chinese Medicine Hospital has regulated the induced differentiation and proliferation of autologous stem cells through extracts from traditional Chinese medicinal materials. It has successfully discovered the "Autologous Stem Cell-Targeted Differentiation Inducer" and applied it to the treatment of irreversible human diseases, demonstrating outstanding scientific research strength. This achievement not only marks the perfect integration of TCM and modern biotechnology, but also reflects Rutai Traditional Chinese Medicine Hospital’s cutting-edge exploration in the field of regenerative medicine.
   In terms of intellectual property rights, Rutai Traditional Chinese Medicine Hospital has published a number of academic papers on this core technology in international authoritative academic journals, which has been recognized by the international medical community. It has also filed a series of domestic and international patents, establishing a solid intellectual property barrier and laying a solid foundation for the subsequent transformation of scientific research achievements and industrial development.
1. Presentation of Academic Achievements
   16 academic papers have been published in international authoritative academic journals.
2. Patent Layout
   12 international PCT patents have been filed, and each international patent has been applied for protection in more than 20 countries and regions, including China, the United States, several countries of the European Union, Japan, Australia, Canada, New Zealand, Singapore, the Hong Kong Special Administrative Region of China, and India.
8 Patents for Vascular Regeneration in the China Region:
Composition of Organic Extracts from Geum japonicum (Great Root Grass) and Its Applications
• Chinese Patent No. ZL01823817.3
• Hong Kong (China) Patent No. HK1068256
Organic Extract of Geum Japonicum (Great Root Grass) and Its Applications
• Chinese Patent No. ZL02830016.5
• Hong Kong (China) Patent No. HK1083191
Pharmaceutical Composition and Method for Muscle Fiber Regeneration in Muscle Injury Treatment
• Chinese Patent No. ZL200680001863.4
• Hong Kong (China) Patent No. HK1112848
Pharmaceutical Composition and Method for Neovascularization/Revascularization in the Treatment of Ischemic Heart Disease
• Chinese Patent No. ZL200680001861.5
• Hong Kong (China) Patent No. HK1110784
3.Laboratory Construction
   After successfully discovering the "Autologous Stem Cell-Targeted Differentiation Inducer", Rutai Traditional Chinese Medicine Hospital has established a brand-new theoretical framework for the radical treatment of cardiovascular and cerebrovascular diseases. The establishment of this new theoretical framework for the radical treatment of such diseases not only provides new ideas for the treatment of diseases such as heart failure, viral myocarditis, and coronary heart disease, but also lays a solid foundation for future research and clinical applications.
   A substantial amount of funds has been invested in establishing laboratories for related diseases, which are equipped with internationally advanced research equipment and instruments, providing an excellent research environment for the research team. The laboratories not only focus on in-depth research on cardiovascular and cerebrovascular diseases but also continuously expand their research fields to explore the potential applications of stem cell technology in the treatment of other diseases.
VI. Clinical Application Effects of Scientific Research Achievements
   These achievements have not only been published in top domestic and international journals but also successfully translated into practical applications. Through rigorous clinical trials and data analysis, we have found that cardiovascular disease patients who received treatment with the "Autologous Stem Cell-Targeted Differentiation Inducer" showed significant improvements in cardiac function indicators and a marked enhancement in quality of life. The clinical application of this scientific research achievement not only brings new therapeutic hope to patients but also further verifies the effectiveness and safety of Rutai Traditional Chinese Medicine Hospital’s regenerative medicine and stem cell technology. Meanwhile, we are actively promoting the application of this scientific research achievement in other related disease fields, aiming to bring benefits to more patients.
●Coronary Heart Disease: Establish collateral circulation to achieve autonomous biological bypass, thereby avoiding the risks of surgical operations.
   It regenerates a large number of collateral circulations and microcirculations to compensate for myocardial blood supply, rejuvenates the coronary artery intima in a relatively short period of time, and prevents the formation of new plaques. This fundamentally resolves various clinical symptoms caused by coronary heart disease, which not only relieves patients from the pain and risks of stent implantation or bypass surgery, as well as the burden and side effects of lifelong medication, but also fundamentally eliminates the potential risk of patients developing further diseases such as myocardial infarction.
●Heart Failure: Compensate for blood supply through collateral circulation and microcirculation, induce myocardial cell regeneration, and restore myocardial function.
   Through drug induction, a large number of collateral circulations and microcirculations are established in ischemic myocardial tissue, which significantly improves myocardial blood supply. Additionally, through myocardial cell regeneration, the heart wall gradually thickens to a normal thickness, and myocardial systolic and diastolic functions are restored—meeting the body’s overall blood supply needs, thereby regaining the body’s normal activity capacity and significantly extending lifespan. Meanwhile, after blood supply is improved, ectopic pacemakers in myocardial cells no longer discharge abnormally, and atrial fibrillation naturally disappears, eliminating the need for patients to undergo ablation. As the heart’s function strengthens, the heart rate of patients with bradycardia will return to approximately 60 beats per minute in a short period of time, making it unnecessary for them to have a cardiac pacemaker implanted.
● Myocardial Bridge: Establish collateral circulation to resolve the local blood supply insufficiency caused by coronary artery compression, thereby ensuring the heart receives adequate blood and oxygen supply.
   It induces the rapid regeneration of a large number of collateral circulations and microcirculations in local myocardium, fully compensates for the blood and oxygen supply to ischemic myocardium, and fundamentally eliminates the clinical symptoms and potential risks of patients caused by congenital cardiovascular diseases.
VII. Transformation of Scientific Research Achievements and Product Layout
   Researchers at Rutai have verified the effectiveness and safety of the "Autologous Stem Cell-Targeted Differentiation Inducer" through clinical trials with a large number of samples. They have also successfully developed innovative products for the treatment of cardiovascular diseases based on EGJ technology in China. These products have not only achieved remarkable results in the domestic market but also gained high recognition from experts at home and abroad.
   Meanwhile, to promote the development of the global heart health initiative, we have specifically developed and produced a health food product—Inducerege—for cardiovascular healthy populations overseas. Integrating the core technology of the "Autologous Stem Cell-Targeted Differentiation Inducer," this product aims to improve global cardiovascular health through regenerative medicine, allowing more people to benefit from the remarkable effects of Rutai's stem cell technology.
   Leveraging the research capabilities and technological advantages of Rutai Traditional Chinese Medicine Hospital, the Inducerege brand will provide safe and effective heart health solutions to consumers worldwide.
1. Domestic Clinical Application
Shenlan Tongmai Yangxin Wan
Drug Introduction:
Shenlan Tongmai Yangxin Wan is developed based on the combination of traditional Chinese medicine (TCM) theory and modern EGJ technology. It integrates multiple precious Chinese medicinal materials and is processed through special techniques.This drug is mainly used for the treatment of ischemic heart diseases such as coronary heart disease, myocardial infarction, heart failure, myocardial bridge, and viral myocarditis, with the effects of dredging collaterals to eliminate stasis, replenishing qi, and activating blood circulation. By activating the expression of genes and miRNAs in the specific signaling pathway for angiogenesis, it induces the regeneration of coronary collateral circulation, compensates for myocardial blood supply, promotes the repair of damaged myocardium, and restores the normal function of the heart.Clinical verification shows that patients can see effects within a short period after taking the drug, and some patients can even achieve pathological cure. It provides a new treatment option for patients with heart diseases.
2.Global Health Food
Inducerege
Product Introduction:
Inducerege Dietary Supplement relies on the core EGJ technology of RuTai Regenerative Medicine and is an innovative global health food. With its unique functions of "vascular regeneration" and "cell regeneration", it can effectively improve various cardiovascular health problems, provide strong support for the heart, and open a new chapter in a healthy life.
VIII. Industrialization Support
   To better realize the industrialization of scientific research achievements and establish a sound industrialization support system, Rutai Traditional Chinese Medicine Hospital has founded Hangzhou Kebo Biopharmaceutical Co., Ltd. in Hangzhou, Zhejiang, China, which focuses on technology R&D and product production in the field of scientific research achievement transformation.
   The company not only owns internationally advanced production equipment and quality inspection systems, which can meet our demand for high-quality biopharmaceutical products, but also has gathered a large number of professionals in the field of biotechnology. This ensures the efficient transformation of scientific research achievements, the excellent quality of products, as well as the safety and effectiveness of relevant products and medicines.
   The company is committed to building a complete industrial chain covering in-depth scientific research and large-scale production, further promoting the upgrading and development of the biopharmaceutical industry. As an important platform for the transformation of scientific research achievements of Rutai Traditional Chinese Medicine Hospital, Hangzhou Kebo Biopharmaceutical Co., Ltd. will continue to play its leading role in the biopharmaceutical industry with the continuous deepening of scientific research and technological innovation, and make greater contributions to advancing the development of human health initiatives in the future.
IX. Brand Mission and Vision
Mission：
“To awaken the innate regenerative power within every human body.”
Vision：
“Inducerege — Where Science Meets the Future of Self-Healing.”